undamentalytics Newsletter
Sign in

Coherus Oncology, Inc. revenue

Coherus Oncology, Inc.'s revenue was $42.2m in fiscal 2025, up 59.8% on the year before. Since fiscal 2012 ($1.9m) it has grown at a compound 26.9% a year. Over the last twelve months it was $50.9m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue23313019020356476327211257264251
Growth on the year before—+44.9%+>999%−3.4%+532.8%−99.2%−100.0%—+33.6%−31.4%−35.4%+21.9%−89.7%+59.8%—
Gross profit———————33943826914198182835
Gross margin———————95.2%92.1%82.4%66.8%38.2%66.9%67.2%68.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Toripalimab $40.8M 96.8% ▲ 113.5%
Other $1.3M 3.2% ▼ 81.6%

From Coherus Oncology, Inc.'s 10-K filed March 9, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Coherus Oncology, Inc. $50.9m 61.0% -34.6%
Ocular Therapeutix, Inc $52.1m -8.1% -1.6%
Gossamer Bio, Inc. $53.3m 32.4% —
Siga Technologies Inc $53.7m -70.1% -18.1%
Tango Therapeutics, Inc. $53.8m 121.5% 16.9%
Nektar Therapeutics $54.6m -27.2% -14.6%

Compare with peers

Head to head: CHRS vs OCULCHRS vs GOSSCHRS vs SIGA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coherus Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coherus Oncology, Inc.